June 18 - June 18
Pharmaceutical elemental impurity analysis (USP<232> and ICHQ3D) following USP<735> X-ray fluorescence spectrometry
Changes to the regulatory requirements for elemental impurity testing with the introduction of USP chapters <232>,<233> and the ICHQ3D guidelines is leading to an industry wide change in the approach to this analysis. In this webinar we introduce the new USP chapters and the ICH guidelines and discuss risk analysis and the need for testing. We will also introduce the new USP chapter <735> X-ray fluorescence spectrometry (XRF) and discuss the development and preliminary results for pharmaceutical calibration standards for elemental impurity testing. Finally, we will take a first look at XRF method validation using a model API.
Recorded on: 18 June 2015
Duration: 47 minutes
Panelist: Dr. Andrew L. Fussell is the pharmaceutical and food segment manager at PANalytical, focused on developing the company’s market position in the pharmaceutical and food industries. He is a registered pharmacist and has received a doctorate from the University of Twente, the Netherlands. His dissertation work investigated pharmaceutical applications of coherent anti-Stokes Raman scattering microscopy.
- Pharmaceutical elemental impurity analysis (USP<232> and ICHQ3D) following USP<735> X-ray fluorescence spectrometry
- 18 June 2015, 16:00 - 18 June 2015, 16:45
- UTC+01:00 Europe/Amsterdam